Owlstone Medical, Cambridge, UK, has launched breath biopsy kits based on the company’s proprietary breath biopsy platform. The new product line enables academic, clinical, and pharmaceutical researchers to discover and validate breath-based biomarkers for early detection of pathogens and precision medicine research.
Owlstone Medical’s breath biopsy platform is a new diagnostic modality capable of detecting biomarkers of disease and exogenous compounds—such as volatile drug metabolites—using breath specimens. The company’s ReCiva breath sampler and new breath biopsy kits ensure consistent and reliable collection of breath samples. Volatile organic compound (VOC) biomarkers present in breath can be analyzed with high sensitivity and selectivity in Owlstone’s breath biopsy services laboratory, or in a researcher’s own laboratory.
“Our goal is to help realize the potential of breath biopsy and make it accessible to the widest research base,” says Billy Boyle, cofounder and chief executive at Owlstone Medical. “By launching kits, we are making the process of collecting and analyzing a sample of breath as straightforward as possible, and ensuring high quality and reproducible results. We want to help researchers to be successful, as this will, in turn, lead to more breath biopsy tests being developed, and further establish breath biopsy as a new industry category across a broad range of applications in early disease detection and precision medicine.”
The company’s kits contain consumables for use with the ReCiva breath sampler, including a disposable breath biopsy mask, and a breath biopsy cartridge to collect, stabilize, and enrich VOCs in breath, enhancing the sensitivity for detection of VOCs. All kit components are manufactured and quality checked to the exacting standards required for the analysis of VOC biomarkers in breath.
For more information, visit Owlstone Medical.